Seres Therapeutics, Inc. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
Seres Therapeutics, Inc. (MCRB) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 12-month period ending 2023-12-31, per its 8-K filed 2024-08-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2024-08-15
- Seres Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2021 was $0.00.
- Seres Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2020 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|
| 2023-12-31 | $0.00 8-K · filed 2024-08-15 |
| 2022-12-31 | $0.00 8-K · filed 2024-08-15 |
| 2021-12-31 | $0.00 10-K · filed 2024-03-05 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |